arrow
N

Nevin John

monash university
H指数:21
被引数:1,922

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Treatment escalation after clinically silent MRI lesions in relapsing-remitting multiple sclerosis

在复发缓解型多发性硬化中,针对临床静息期MRI病灶的治疗升级

Brain
IF11.7
2026-07-240
OAAI
Causal effects of multiple sclerosis therapies in left-truncated registry data

多发性硬化疗法在左截断登记数据中的因果效应

2026-07-210
PRE
Utility, validity, feasibility and acceptability of a clinician-administered depression, two-question screening tool for routine multiple sclerosis clinic administration

临床医生管理的抑郁症两问题筛查工具在常规多发性硬化症门诊管理中的实用性、有效性、可行性和可接受性

2026-04-260
PRE
Predicting disease progression in multiple sclerosis with clinically accessible information and technology

利用临床可获取的信息和技术预测多发性硬化症的疾病进展

2026-04-190
OAAI
Preserving Neurological Function in People at High and Low Risk of Aggressive Multiple Sclerosis: An Observational Cohort Study

在高危和低危侵袭性多发性硬化患者中保留神经功能:一项观察性队列研究

2026-04-040
OAAI
Comparative effectiveness of anti-CD20 therapies and S1P receptor modulators in late-onset multiple sclerosis: real-world evidence from the MSBase registry

抗CD20疗法与S1P受体调节剂在迟发性多发性硬化中的比较疗效:来自MSBase注册研究的真实世界证据

2026-03-260
PRE
Vascular Comorbidities and an Increased Comorbidity Score Are Associated With Disability and Disability Progression in Secondary Progressive Multiple Sclerosis

血管合并症和升高的合并症评分与继发性进展型多发性硬化中的残疾及残疾进展相关

2026-02-090
OA
Effect of late-onset on multiple sclerosis phenotype and outcome: evidence from a multi-national registry

迟发性对多发性硬化表型和结局的影响:多国注册研究的证据

2026-02-040
PRE
Real-world effectiveness of horizontal switching between disease-modifying therapies in multiple sclerosis: a retrospective analysis of the MSBase Registry

多发性硬化疾病 modifying therapies 之间水平切换的实效性:MSBase 注册数据库的回顾性分析

2025-12-230
PRE
The ABILHAND-23 Patient Reported Outcome Measure in Secondary Progressive Multiple Sclerosis: A Cross-Sectional Analysis With the Nine Hole Peg Test

ABILHAND-23患者报告结局测量在继发性进展型多发性硬化中的应用:一项与九孔钉板测试的横断面分析

2025-11-260
OAAI
Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trial

他汀类药物再利用对继发性进展型多发性硬化症(MS-STAT2)残疾进展的影响:一项III期、随机、双盲、安慰剂对照试验

2025-10-010
OAAI
Persistent progression independent of relapse activity in multiple sclerosis

多发性硬化中与复发活动无关的持续性进展

2025-08-210
OAAI
Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis

造血干细胞移植与免疫重建疗法在复发型多发性硬化中的比较

Brain
IF11.7
2025-08-040
PRE
Personalized federated learning for predicting disability progression in multiple sclerosis using real-world routine clinical data

基于真实世界常规临床数据的个性化联邦学习在预测多发性硬化致残进展中的应用

2025-07-240
OAAI
Four years on: Pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women’s Health Registry (2020–2024)

四年之后:MSBase妊娠、新生儿结局及女性健康登记册(2020–2024)中报告的妊娠与分娩结局

2025-07-070
PRE
Optical coherence tomography in secondary progressive multiple sclerosis: cross-sectional and longitudinal exploratory analysis from the MS-SMART randomised controlled trial
2024-12-180
PRE